Thymopentin (TP-5) is a synthetic five-amino-acid peptide derived from the thymus gland, used to modulate immune function — primarily by restoring T cell activity in immunocompromised states and, more recently, investigated for antitumor applications.
What it does
Thymopentin is a pentapeptide (five amino acids: Arg-Lys-Asp-Val-Tyr) that mimics a fragment of thymopoietin, a hormone produced by the thymus — the gland responsible for maturing T cells, the immune system's primary adaptive fighters. By binding to T cell precursors and signaling through the thymic microenvironment, TP-5 encourages the differentiation and activation of T cells that might otherwise remain immature or dysfunctional PubMed 41153776.
In mouse tumor models, TP-5 showed a particularly interesting effect: it promoted thymic rejuvenation — essentially coaxing a shrunken or underperforming thymus back toward normal output — and restored the balance between thymus-generated immunity and tumor-driven immune suppression PubMed 41153776. It also appeared to reprogram 'exhausted' T cells, a state where T cells lose their killing ability after prolonged exposure to tumors or chronic infection, restoring their effector function (the ability to actually kill target cells) without triggering runaway inflammation PubMed 41153776. Beyond cancer, TP-5 has been studied for its role in gut immunity, where it stimulated IL-22 production — a cytokine that helps maintain the intestinal barrier — in colitis models PubMed 31695782.
What the evidence shows
Antitumor immunity Strong rodent evidence across multiple tumor models; no published human trial data for oncology yet
A 2025 study tested TP-5 across four murine (mouse) tumor models — B16-F10 melanoma, MC38 colorectal carcinoma, Hepa 1-6, and LM3 hepatocellular carcinoma — and found it significantly suppressed tumor growth through T cell-dependent mechanisms PubMed 41153776. Depleting T cells abolished the effect, confirming the antitumor activity is not a direct cytotoxic action on cancer cells but an immune-mediated one. TP-5 also showed additive benefit when combined with adoptive T cell therapy (a treatment where a patient's T cells are expanded outside the body and reinfused), enhancing both T cell proliferation and function PubMed 41153776. This is promising, but all evidence is currently in animals — no human oncology trials have been published.
HIV and immune deficiency Clinical trial conducted; results limited and dated
A double-blind study enrolled asymptomatic HIV-infected patients receiving antiretroviral therapy (AZT, ddI, or combinations) to evaluate whether thymopentin could improve immune parameters NCT00002109. The trial was registered but comprehensive published outcome data are not widely available in the current literature. Given that this was conducted in an era predating modern antiretroviral regimens, its relevance to contemporary HIV management is unclear.
Inflammatory bowel disease Rodent evidence only
In a dextran sulfate sodium-induced colitis mouse model — a standard preclinical stand-in for inflammatory bowel disease — TP-5 reduced intestinal inflammation by triggering IL-22 production from both innate lymphoid cells and adaptive T cells PubMed 31695782. IL-22 is a key cytokine for gut barrier repair. There are no human IBD trials to date.
Autoimmune neuroinflammation Rodent evidence only
In mice with experimental autoimmune encephalomyelitis (EAE) — a model used to study multiple sclerosis — thymic peptides including thymopentin dampened the inflammatory response PubMed 22727332. The mechanism appears to involve restraining pro-inflammatory signaling rather than broad immune suppression. Again, no human data exist for this application.
Formulation and delivery research Preclinical/pharmaceutical only
Because TP-5 degrades rapidly in the body, researchers have explored bioresorbable hydrogel systems using PLA-PEG-PLA polymers to create sustained-release formulations PubMed 19895878, as well as water-soluble alginic acid conjugates to protect the peptide's N-terminus from enzymatic breakdown PubMed 37764221. These are pharmaceutical development efforts, not clinical efficacy studies, but they matter because TP-5's short half-life is a real practical limitation.
How it's used
In historical clinical studies and self-reported protocols, thymopentin has most commonly been administered by subcutaneous (under the skin) or intramuscular injection. Doses in older clinical contexts typically ranged from 50 mg administered several times per week, though specific regimens varied considerably by indication and study design. The recent murine antitumor research used weight-based dosing in animals, which does not translate directly to human equivalents. A phase 1 first-in-human ascending dose study for a related compound (FC-12738) is registered NCT05978908, suggesting renewed interest in establishing human pharmacokinetic data. In studies and self-reported protocols, dosing frequency has ranged from daily to three times per week, with cycles varying from weeks to months. Half-life data are not well-characterized in current literature, which is part of why sustained-release delivery systems are an active area of research PubMed 19895878.
Side effects and safety
Reported mild effects include injection site reactions, low-grade fever, and fatigue. Moderate effects seen in some users include flu-like symptoms and joint pain (arthralgia). The more serious theoretical risks involve autoimmune flares — because TP-5 stimulates T cell activity, anyone with an underlying autoimmune condition could experience a worsening of their disease. Severe immune reactions have been listed as a potential adverse event, though these appear rare in the available literature. TP-5 is absolutely contraindicated in people on active transplant immunosuppression, where stimulating T cells could trigger organ rejection. Relative contraindications include active infection, existing autoimmune disease, and other forms of immunosuppression. Long-term safety data in humans are sparse — most published studies are short-duration or preclinical, and the consequences of extended T cell stimulation over months to years are simply not known.
Bottom line
Thymopentin has a real and well-characterized mechanism — it genuinely activates T cell immunity via the thymus — and the 2025 rodent tumor data are legitimately interesting, particularly the exhaustion-reversal and thymic rejuvenation findings PubMed 41153776. However, human evidence is thin and largely dated; there are no published human efficacy trials for its most exciting proposed uses. Anyone with autoimmune conditions or on immunosuppressive therapy should treat this as a hard contraindication, not a caution.